Clinical Trial Update: Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating single-agent idelalisib followed by idelalisib in combination with chemotherapy in adults with metastatic pancreatic ductal adenocarc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Idelalisib (idelalisib)

Snippet

Sponsor: Gilead Sciences | Conditions: Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: TERMINATED | Results posted: 2021-03-22